Microcap Ledger Apyx Medical Corp $APYX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Clearwater, FL
- Fiscal year end
- December 31
- Shares outstanding
- 42,124,023 [10-Q 2026-08-06]
What the company doesAI summary of filing
Apyx Medical Corporation is a revenue-generating surgical aesthetics company that develops and sells energy-based medical devices for cosmetic and surgical procedures. The company's primary products are its Helium Plasma Technology platforms marketed as Renuvion for cosmetic surgery and J-Plasma for hospital surgical settings, as well as the AYON Body Contouring System, which received FDA clearance in May 2025 and commenced commercial launch in September 2025. The company generates revenue through direct sales in the U.S. and through an international distributor network, and also manufactures products for other medical device companies through OEM agreements. As of December 31, 2025, the company had cash of $31.7 million, incurred a loss from operations of $6.4 million, and had 205 full-time employees worldwide. [10-K 2026-03-10]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $26.37M | −$5.35M | −$4.06M | $27.62M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $52.84M | −$11.21M | −$8.00M | $31.74M | [10-K 2026-03-10] |
| FY ended Dec 2024 | $48.10M | −$23.46M | −$18.05M | $31.74M | [10-K 2026-03-10] |
- Quarterly cash burn
- −$2.03M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-06 | 34,643,886 | [10-Q 2024-11-08] |
| 2025-03-11 | 37,793,886 | [10-K 2025-03-13] |
| 2025-05-07 | 37,793,886 | [10-Q 2025-05-08] |
| 2025-08-05 | 37,819,478 | [10-Q 2025-08-07] |
| 2025-11-05 | 38,241,905 | [10-Q 2025-11-06] |
| 2026-03-09 | 41,829,226 | [10-K 2026-03-10] |
| 2026-05-06 | 41,873,951 | [10-Q 2026-05-07] |
| 2026-08-05 | 42,124,023 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2025-12-01; declared effective 2025-12-16 [S-3 2025-12-01]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | Waldman Lawrence | exercise | 12,000 | $1.88 | [4 2026-07-02] |
| 2026-06-30 | Waldman Lawrence | other | 5,024 | $4.49 | [4 2026-07-02] |
| 2026-06-15 | Roman Shawn David | exercise | 15,000 | $3.23 | [4 2026-06-17] |
| 2026-06-15 | Roman Shawn David | other | 10,533 | $4.60 | [4 2026-06-17] |
| 2026-06-11 | Vizirgianakis Stavros G. | grant | 450,000 | — | [4 2026-06-15] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Other events |
| 2026-08-07 | 8-K | Director or officer change; Shareholder vote results |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-07-24 | 8-K | Other events |
| 2026-07-21 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-26 | DEF 14A | Proxy statement |
| 2026-06-17 | 8-K | Material agreement entered |
| 2026-05-21 | 8-K | Other events |
| 2026-05-14 | 8-K | Other events |
| 2026-05-11 | 8-K | Other events |
| 2026-05-07 | 10-Q | Quarterly report |
Alerts for $APYX
Email me when Apyx Medical Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.